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Abstract
Objective: C-peptide is derived from proinsulin and it is secreted in equimolar concentration with insulin. 
Plasma C-peptide is more stable than insulin and it provides an indirect measure of insulin secretory 
reserve and beta cell function. To determine relationship between C-peptide and duration of diabetes 
mellitus, age, body mass index, systolic blood pressure and diastolic blood pressure. 
Methods: This is a cross-sectional study of type 2 diabetes mellitus patients attending Endocrine Clinic. 
Information such as age, sex, height, weight, blood pressure and duration of diabetes were obtained. Blood 
samples were taken for fasting serum C-peptide. Data was analysed using SPSS version 16. 
Results: Out of the 46 subjects recruited 23 (50%) were females and 23 (50%) were males. The mean age 
was 55.63 ± 14.7 years. Mean duration of diabetes for both sexes was 8 years with a range of 1 to 32 years. 
2 2The mean BMI was 26.87 ± 5.00 kg/m for males and 30.09 ± 4.32 Kg/m  for females. The mean fasting 
serum C-peptide was 2.16 ± 1.41 ng/ml and there was no significant difference between males and 
females. There is statistically significant inverse correlation between C-peptide and duration of diabetes 
(r= -0.356, p= 0.015). Conversely there is a direct relationship between C-peptide and BMI (r=0.307, 
p=0.038). 
Conclusion: Increasing duration of diabetes is associated with decreasing level of C-peptide and 
decreased beta cell secretory reserve. 
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Connexion peptide (c-peptide) et la durée du diabète sucré chez les 
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Resume
Objectif: C-peptide est dérivé de la pro-insuline et il est sécrété à une concentration équimolaire avec 
l'insuline. Plasma peptide C est plus stable que l'insuline et elle fournit une mesure indirecte de la réserve 
de sécrétion d'insuline et la fonction des cellules bêta. Pour déterminer la relation entre C-peptide et la 
durée du diabète sucré, l'âge, indice de masse corporelle, la pression artérielle systolique et de la pression 
artérielle diastolique.
Méthodes: Ceci est une étude transversale des patients diabétiques de type 2 mellitus fréquentant 
Endocrine Clinic. Des informations telles que l'âge, le sexe, la taille, le poids, la tension artérielle et la 
durée du diabète ont été obtenus. Des échantillons de sang ont été prélevés pour sérique à jeun du C-
peptide. Les données ont été analysées à l'aide du logiciel SPSS version 16.
Résultats: Sur les 46 sujets recrutés 23 (50%) étaient des femmes et 23 (50%) étaient des hommes. L'âge 
moyen était de 55,63 ± 14,7 années. la durée du diabète moyenne pour les deux sexes était de 8 ans avec 
une gamme de 1 à 32 ans. L'IMC moyen était de 26,87 ± 5,00 kg / m2for hommes et 30,09 ± 4,32 kg / m2 
pour les femmes. Le sérum moyen jeûne C-peptide était de 2,16 ± 1,41 ng / ml et il n'y avait pas de 
différence significative entre les hommes et les femmes. Il existe statistiquement significative corrélation 
inverse entre le peptide C et la durée du diabète (r = -0,356, p = 0,015). A l'inverse, il existe une relation 
directe entre le C-peptide et l'IMC (r = 0,307, p = 0,038).
Conclusion: L'augmentation de la durée du diabète est associé à niveau de C-peptide diminuant et une 
diminution de la bêta réserve sécrétoire cellulaire.
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INTRODUCTION
Insulin is an essential hormone produced 
in the pancreas and is invaluable in carbohydrate 
metabolism. It also plays important roles in 
protein and lipid metabolism. Insulin is derived 
from a prohormone called proinsulin. C-peptide 
is derived from proinsulin in equimolar 
proportion with insulin. Proinsulin is derived 
from preproinsulin secreted by the beta cells of 
 the endocrine pancreas (1, 2). Preproinsulin has 
110 amino acids and proinsulin has 86 amino 
acids. Insulin has a double chain with 51 amino 
acids while C-peptide has 31 amino acids. 
C-peptide derives its name because it connects 
the A and B chains of insulin in the pro-insulin 
molecule. While the liver clears a significant 
portion of insulin (50-60%) in a first pass; C-
peptide does not undergo hepatic extraction and 
has constant peripheral clearance at various 
plasma glucose concentrations unlike insulin. It 
is excreted through the kidneys and its plasma 
half-life is about 30 minutes unlike plasma 
insulin with a half-life of 4 minutes. For these 
reasons plasma C-peptide levels may be more 
reliable than insulin in assessing beta-cell 
. 
function (3)
Plasma C-peptide was previously 
considered an inactive peptide but recent study 
suggests that it is an active peptide involved in 
glucose transport  and st imulat ion of  
microvascular blood flow (4).
Measurement of plasma C-peptide has attained 
increased significance following the findings 
from Diabetes Control and Complication Trial 
(DCCT) which demonstrated that higher C-
peptide is associated with decreased incidence of 
diabetic retinopathy and nephropathy in subjects 
 living with diabetes(5). Another study has shown 
that serum C-peptide is an independent risk factor 
for cardiovascular disease, cancer and total 
 mortality(6). 
In a study of elderly diabetics in India, 
fasting C-peptide was increased in obese subjects 
when compared to non-obese individuals 
 indicating insulin resistance (7). It also showed 
decreasing levels of C-peptide with increasing 
duration of diabetes. In Nigeria Oli et al 
demonstrated that type 2 diabetic subject with 
poor glycemic control had lower fasting and post-
 glucagon stimulation C-peptide (8). In another 
study in Northern Nigeria, type 2 diabetes 
subjects were found to have lower beta cell 
 
reserve using C-peptide(9). 
At the time of diagnosis of type 2 diabetes 
mellitus, about 50% of beta cell function has been 
lost, and this deteriorates by about 4% yearly. In 
normal non-diabetic population from the age of 
40 years, the rate of beta cell decline is 1%. The 
causes of beta cell dysfunction are multifactorial 
and include genetic, obesity, hyperglycaemia, 
dyslipidaemia, and hormonal (10, 11). Serum C-
peptide is used in distinguishing type 1 from type 
2 diabetes and evaluation of hypoglycaemia. 
Persistence of C-peptide is an important feature 
of maturity onset diabetes of the young (MODY). 
It helps to identify these patients as they are 
commonly misdiagnosed as type 1 diabetes.
The normal fasting reference value in Federal 
Medical Centre, Owerri is 0.7 – 1.9ng/ml (234-
635 pmol/l). The objective of this study is to 
evaluate the relationship between serum C-
peptide with duration of diabetes, body mass 
index, systolic and diastolic blood pressures. 
MATERIALS AND METHODS
A cross sectional study of subjects with 
type 2 diabetes mellitus attending the Endocrine 
Medical Out-Patient Clinic of FMC Owerri, 
between June 2013 and May. Subjects were 
recruited by systematic random sampling of 
patients living with diabetes. Age and duration of 
diabetes was assessed from the records. Height 
was measured to the nearest 0.5 cm using a 
stadiometer. Weight was measured to the nearest 
0.5kg using a weighing scale. Body mass index 
was calculated by body weight divided by the 
square of height. Blood pressure was measured 
using Accoson mercury sphygmomanometer to 
determine the brachial systolic and diastolic 
blood pressures. 
Venous blood after 10-12hours overnight 
fast, were collected into plain specimen 
containers. The samples were left to stand for 
about 20mins for clot retraction, after which they 
were spun at 3000rmp for 5mins and serum were 
collected for C-peptide assay. Serum C-peptide 
level was analyzed with Accubind C-peptide 
enzyme linked immunosorbent assay kit 
(MonobindInc, Lake forest, CA USA)  Data was 
analysed using the statistical package for social 
science (SPSS) version 16. Continuous variables 
will be expressed as mean ± standard deviation 
and categorical variables will be expressed as 
frequency table and chart. The relationship 
between C-peptide and duration of diabetes, 
blood pressures and body mass index was 
determined using Pearson correlation coefficient. 
Test of significance was set at p-value ≤ 0.05 
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RESULTS 
Subjects who had diabetes for less than 
one year had the highest value of fasting C-
peptide 3.63 ng/mL while the lowest level 0.5 
ng/mL was seen in those with diabetes lasting 
more than 31 years. 21.7% of the subjects had C-
peptide less than 0.9 ng/mL and 23.9% had C-
peptide greater than 3.0 ng/mL. There was a 
moderate positive correlation between body mass 
index and C-peptide (r=370, p=0.011) and a 
moderate negative correlation between duration 
of diabetes and C-peptide (r= -366, p=0.012). 
DISCUSSION 
C-peptide levels was higher in subjects whose 
duration of diabetes was less than one year and 
there was a progressive decline as the duration of 
diabetes increases ( figure 1). There was also 
moderate negative correlation between fasting C-
peptide and duration of diabetes (r= -366, 
p=0.012). This findings is similar to other studies 
(12, 13), which described progressive beta cell 
decline as the hallmark of type 2 diabetes 
mellitus. This however, contrast with the study by 
Young et al (14) who did not find any statistical 
significant decline of C-peptise with increasing 
duration of diabetes. The findings of slightly 
higher C-peptide in the group of subjects with 
duration of diabetes 16-20 years may be due to 
o ther  fac tors .  These  fac tors  inc lude 
hyperglycemia, increased adiposity, genetic 
factors, type of anti-diabetic medications and 
renal failure (15).  There was no significant 
correlation between C-peptide and the age of the 
subjects. This may be due to variable onset of 
diabetes among the subjects.
Obesity which is a key risk factor for 
diabetes mellitus contributes significantly to 
development of insulin resistance. In this study 
2
the mean body mass index was 28.40±4.9 kg/m .  
Females had significantly higher body mass 
index than males (p=0.024). Obesity is increasing 
in most populations (16, 17, 18) and this has 
contributed to increasing prevalence of diabetes. 
Physical inactivity, food high in saturated fat and 
simple sugar has contributed tremendously to the 
global rise in the incidence and prevalence of 
obesity (19). Higher insulin values in obesity 
A total of 46 subjects were included in 
the analysis, 23 (50%) males and 23 (50%) 
females. Males and female subjects were similar 
with respect to mean age, duration of diabetes, 
systolic blood pressure, diastolic blood pressure 
and fasting C-peptide. Mean body mass index 
was significantly higher in female subjects at 
p=0.024. 
signify an attempt by the body to overcome 
insulin resistance associated with obesity. 
Hyperinsulinemia, a consequence of obesity in 
diabetes contributes to vascular endothelial 
damage. 
CONCLUSION
The low beta cell reserve in some subjects living 
with diabetes mellitus and the progressive 
decline of beta cell function with increasing 
duration of diabetes necessitate the need for early 
initiation of appropriate treatment to reduce the 
rate of beta cell exhaustion. This will also help 
improve glycemic control and reduce onset of 
complications. 
Routine assessment of beta cell function using C-
peptide at diagnosis should be considered in the 
management of diabetes. This will help in 
choosing appropriate antidiabetic medications. 
Obesity remains a major problem among subjects 
with type 2 diabetes. There is the need to 
emphasize on lifestyle modifications which may 
include medical nutrition therapy and physical 
exercise with the aim of achieving good body 
mass index. 
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Table 1. Characteristics of male and female subjects
Male Female
n 23 23
Age (years) 58.30 ± 16.21 53.00 ± 12.96
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Table 2. Correlation table between age, duration of diabetes, body mass index, systolic blood 









































































































































































































































































        
 
